Notable from Our Podcast
In the July 23, 2019, podcast, Dr. Gregory Day spoke with Dr. Philip Insel about his article on determining clinically meaningful decline in preclinical Alzheimer disease.
Author Tip
E-alerts
Want to easily keep track of new articles published in Neurology ® in your field of interest? Sign up for e-alerts! You can customize alerts to be emailed to you about new articles by subject, title, and author. You can also get the table of contents of all or some of the Neurology journals. To sign up, visit NPub.org/alerts.
From the AAN Press Room
Visit AAN.com/pressroom for the latest press releases
What Factors Help Predict Who Will Keep Their Memory into Their 90s?
Why do some people stay sharp into their 90s, even if they have the amyloid plaques in the brain associated with Alzheimer disease (AD)? Why do others reach their 90s without developing plaques? In a new study, researchers found that people with normal scores on thinking and memory tests at the start of the study were less likely to develop later cognitive problems, even if they had amyloid plaques. “This finding is consistent with the theory that people with better lifelong thinking and memory skills have a ‘cognitive reserve’ that provides a buffer of protection against changes in the brain,” said study author Beth E. Snitz, PhD. Researchers also found that people with the gene variant called APOE e2, which has been associated with a decreased risk of AD, were more resistant to developing amyloid plaques than people without the variant.
Predicting resistance to amyloid-beta deposition and cognitive resilience in the oldest old doi.org/10.1212/WNL.0000000000010239
CME
Five years of ocrelizumab in relapsing multiple sclerosis: OPERA studies open-label extension
Page 577
Neurologic and neuroimaging findings in patients with COVID-19: A retrospective multicenter study
Page 578
Most-Read Articles
As of July 28, 2020
Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDA Work Group* under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease
G. McKhann, D. Drachman, M. Folstein, et al. 1984;34:939–944. doi.org/10.1212/WNL.34.7.939
Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)
J.F. Kurtzke. 1983;33:1444–1452. doi.org/10.1212/WNL.33.11.1444
Parkinsonism: onset, progression, and mortality
M.M. Hoehn and M.D. Yahr. 1967;17:427–442. doi.org/10.1212/WNL.17.5.427
Frontotemporal lobar degeneration: A consensus on clinical diagnostic criteria
D. Neary, J. S. Snowden, L. Gustafson, et al.1998;51:1546-1554. doi.org/10.1212/WNL.51.6.1546
Neurosurgical horizons in Parkinson's disease
C.G. Goetz, M.R. De Long, R.D. Penn, and R.A.E. Bakay. 1993;43:1–7. doi.org/10.1212/WNL.43.1_Part_1.1
- © 2020 American Academy of Neurology
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
